Physician profile
James D Walker
NPI 1376638973
$3,507.89
in general payments reported to CMS, 2019-2025
38 companies · $577 in 2025
The $577 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $211 · 2020: $313 · 2021: $656 · 2022: $722 · 2023: $345 · 2024: $685 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,441.44 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $745.59 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $437.66 | 2019-2025 | Vraylar |
| Astellas Pharma US INC | $397.14 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $340.51 | 2019-2025 | |
| Novo Nordisk INC | $253.38 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $224.26 | 2020-2022 | |
| Amgen INC. | $212.31 | 2019-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $182.42 | 2021-2025 | Jardiance, Zepbound, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.06 | 2022-2024 | Jardiance, Ofev |
| Otsuka America Pharmaceutical, INC. | $54.60 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $53.34 | 2021-2023 | Vaxneuvance, Gardasil 9 |
| Ibsa Pharma INC. | $41.84 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $39.07 | 2024-2025 | Nuzyra, Xhance |
| Abbott Laboratories | $29.42 | 2021-2023 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.34 | 2025 | Caplyta |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $24.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.51 | 2019 | |
| Corium, LLC | $20.82 | 2022 | |
| Aimmune Therapeutics, INC. | $20.64 | 2025 | Zenpep |
| Ascensia Diabetes Care US INC. | $20.63 | 2025 | |
| Boston Scientific Corporation | $20.01 | 2021 | |
| Phathom Pharmaceuticals, INC. | $19.14 | 2024 | Voquezna |
| Abiomed | $18.80 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $18.50 | 2021 | |
| Exact Sciences Corporation | $18.38 | 2025 | Cologuard Collection Kit |
| Biogen, INC. | $18.35 | 2022 | |
| Allergan, INC. | $18.07 | 2020 | |
| Lundbeck LLC | $17.88 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.43 | 2025 | Xifaxan |
| Cardiovascular Systems INC. | $16.94 | 2021 | |
| Currax Pharmaceuticals LLC | $15.98 | 2025 | Contrave |
| Horizon Therapeutics Plc | $15.97 | 2020 | |
| Dexcom, INC. | $15.67 | 2022 | |
| Ascendis Pharma Endocrinology INC | $14.41 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $14.35 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $13.28 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.70 | 2021 | |
| Esperion Therapeutics, INC. | $12.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.